|
|||||
|
|
| 健脾益肾、活血化痰法联合罗格列酮早期治疗非酒精性脂肪肝并胰岛素抵抗29例临床观察 | |
| 引用本文： | 姜海伟,和单凤,肖会泉.健脾益肾、活血化痰法联合罗格列酮早期治疗非酒精性脂肪肝并胰岛素抵抗29例临床观察[J].中医杂志,2008,49(11):981-983. |
| 作者姓名： | 姜海伟 和单凤 肖会泉 |
| 作者单位： | 1. 湖北省中山医院亚健康管理中心,武汉市中山大道26号,430033 2. 湖北省中山医院内科 3. 广州中医药大学第一附属医院 |
| 摘 要： | 目的 探讨健脾益肾、活血化痰法联合罗格列酮对非酒精性脂肪肝并胰岛素抵抗的早期治疗意义.方法 90例患者随机分为空白组29例、西药组(口服罗格列酮)32例、治疗组(口服罗格列酮和健脾益肾、活血化痰方)29例,1个月为1个疗程,共2个疗程.观察治疗前后肝功能、血脂、空腹血糖(FBG)、空腹胰岛素(FINS)、胰岛素抵抗指数(IRI)、血清瘦素、脂联索的变化.结果 治疗组患者肝功能、血脂、FBG、FINS、IRI、瘦素、脂联素与治疗前比较差异均有统计学意义(P＜0.05或＜0.01);与西药组比较,在改善7-谷氨酰转肽酶(GGT)及FINS方面差异有统计学意义(P＜0.05或＜0.01).治疗组总有效率79.31%.结论 健脾益肾、活血化痰法联合罗格列酮早期干预非酒精性脂肪肝并胰岛素抵抗有着较好的临床意义. |
| 关 键 词： | 健脾益肾 活血化痰 罗格列酮 非酒精性脂肪肝 胰岛素抵抗 |
Clinical Study on 29 Cases of Nonalcoholic Fatty Liver Disease with Insulin Resistance Treated by Strengthening Spleen,Tonifying Kidney,Invigorating Blood Flow and Dissolving Phlegm plus Rosiglitazone |
|
| JIANG Hai-wei,HE Dan-feng,XIAO Hui-quan.Clinical Study on 29 Cases of Nonalcoholic Fatty Liver Disease with Insulin Resistance Treated by Strengthening Spleen,Tonifying Kidney,Invigorating Blood Flow and Dissolving Phlegm plus Rosiglitazone[J].Journal of Traditional Chinese Medicine,2008,49(11):981-983. | |
| Authors: | JIANG Hai-wei HE Dan-feng XIAO Hui-quan |
| Institution: | JIANG Hai-wei1,HE Dan-feng2,XIAO Hui-quan3(1.Health Administration Center,Zhongshan Hospital of Hubei Province,Wuhan 430033,2.Internal Department,3.First Affiliated Hospital of Guanghzou University of Chinese Medicine) |
| Abstract: | Objective To observe the effect of herbal treatment to strengthen spleen,tonify kidney,invigorate blood flow and dissolve phlegm plus Rosiglitazone on nonalcoholic fatty liver disease (NAFLD) with insulin resistance (IR).Methods The 90 cases were randomized into 3 groups:blank group of 29 cases;western medicine group of 32 cases,treated with Rosiglitazone;treatment group of 29 cases treated with herbal medicine plus Rosiglitazone.The changes in liver function,blood lipid,fasting blood glucose (FBG),fasting ... |
| Keywords: | Strengthen spleen tonify kidney invigorate blood flow dissolve phlegm Rosiglitazone Nonalcoholic fatty liver disease (NAFLD) Insulin resistance (IR) |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ | |